Therapeutic options for carbapenemase-producing Enterobacteriaceae;Tratamiento de infecciones causadas por enterobacterias productoras de carbapenemasas

Revista Espanola de Quimioterapia

Volumn 28, Issue , 2015, Pages 12-15

  Salgado, Patricia ^a   Gilsanz, Fernando ^a   Maseda, Emilio ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FOSFOMYCIN; GENTAMICIN; POLYMYXIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CARBAPENEMASE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE INFECTION; DRUG EFFECT; DRUG POTENTIATION; ENTEROBACTERIACEAE INFECTION; NONHUMAN; PRACTICE GUIDELINE; PUBLIC HEALTH PROBLEM; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; HUMAN; METABOLISM;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS;

EID: 84942873057     PISSN: 02143429     EISSN: 19889518     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10:597-602.
2. Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2014;20:862-72.
3. Rodriguez-Baño J, Cisneros JM, Gudiol C, Martinez JA. Treatment of infections caused by carbapenemase-producing Enterobacteriaceae. Enferm Infecc Microbiol Clin 2014;32 (Suppl 4):49-55.
4. Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, Carmeli Y, Paul M. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 2013;57:5104-11.
5. Urban C, Mariano N, Rahal JJ. In vitro double and triple bactericidal activities of 62 doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob. Agents Chemother 2010; 54:2732–4.
6. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012;25:682-707.
7. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 2005;18:306-25.
8. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012;55:943-50.
9. Rodriguez-Baño J, Cisneros JM, Cobos-Trigueros N, Fresco G, Navarro-Sanfrancisco C, Gudiol C, et al. Executive summary of the diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Enferm Infecc Microbiol Clin 2015;33:337.e1-337.e21.